A Nationwide Study on HER2-Low Breast Cancer in South Korea: Its Incidence of 2022 Real World Data and the Importance of Immunohistochemical Staining Protocols
- Author:
Min Chong KIM
1
;
Eun Yoon CHO
;
So Yeon PARK
;
Hee Jin LEE
;
Ji Shin LEE
;
Jee Yeon KIM
;
Ho-chang LEE
;
Jin Ye YOO
;
Hee Sung KIM
;
Bomi KIM
;
Wan Seop KIM
;
Nari SHIN
;
Young Hee MAENG
;
Hun Soo KIM
;
Sun Young KWON
;
Chungyeul KIM
;
Sun-Young JUN
;
Gui Young KWON
;
Hye Jeong CHOI
;
So Mang LEE
;
Ji Eun CHOI
;
Ae Ri AN
;
Hyun Joo CHOI
;
EunKyung KIM
;
Ahrong KIM
;
Ji-Young KIM
;
Jeong Yun SHIM
;
Gyungyub GONG
;
Young Kyung BAE
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2024;56(4):1096-1104
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Notable effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer (BC) has focused pathologists’ attention. We studied the incidence and clinicopathologic characteristics of HER2-low BC, and the effects of immunohistochemistry (IHC) associated factors on HER2 IHC results.
Materials and Methods:The Breast Pathology Study Group of the Korean Society of Pathologists conducted a nationwide study using real-world data on HER2 status generated between January 2022 and December 2022. Information on HER2 IHC protocols at each participating institution was also collected.
Results:Total 11,416 patients from 25 institutions included in this study. Of these patients, 40.7% (range, 6.0% to 76.3%) were classified as HER2-zero, 41.7% (range, 10.5% to 69.1%) as HER2-low, and 17.5% (range, 6.7% to 34.0%) as HER2-positive. HER2-low tumors were associated with positive estrogen receptor and progesterone receptor statuses (p < 0.001 and p < 0.001, respectively). Antigen retrieval times (≥ 36 minutes vs. < 36 minutes) and antibody incubation times (≥ 12 minutes vs. < 12 minutes) affected on the frequency of HER2 IHC 1+ BC at institutions using the PATHWAY HER2 (4B5) IHC assay and BenchMark XT or Ultra staining instruments. Furthermore, discordant results between core needle biopsy and subsequent resection specimen HER2 statuses were observed in 24.1% (787/3,259) of the patients.
Conclusion:The overall incidence of HER2-low BC in South Korea concurs with those reported in previously published studies. Significant inter-institutional differences in HER2 IHC protocols were observed, and it may have impact on HER2-low status. Thus, we recommend standardizing HER2 IHC conditions to ensure precise patient selection for targeted therapy.
